Search results for "interleukin-1"

showing 10 items of 660 documents

Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10

1997

SUMMARY Sinusoidal endothelial cells and Kupffer cells are the first cell populations in the liver that come into contact with gut-derived endotoxin in portal blood. Although endotoxin concentrations as high as 1 ng/ml are physiologically present in portal blood, no local inflammation is seen. We show that the proinflammatory cytokine IL-6, which is central to the development of inflammatory reactions in the liver, is produced by sinusoidal endothelial cells and Kupffer cells in response to low concentrations of endotoxin (100 pg/ml to 1 ng/ml). The anti-inflammatory cytokine IL-10 down-regulated endotoxin-induced IL-6 release in endothelial and Kupffer cells. Importantly, Kupffer cells sec…

medicine.medical_specialtyEndotheliumKupffer Cellsmedicine.medical_treatmentImmunologyInflammationBiologyProinflammatory cytokineMiceInternal medicinemedicineAnimalsImmunology and AllergyInterleukin 4Mice Inbred BALB CInterleukin-6MicrocirculationKupffer cellOriginal ArticlesInterleukin-10EndotoxinsEndothelial stem cellInterleukin 10medicine.anatomical_structureCytokineEndocrinologyLiverImmunologyEndothelium Vascularmedicine.symptomClinical and Experimental Immunology
researchProduct

Exacerbation of ulcerative colitis after rituximab salvage therapy

2007

Background: B-cells are considered to play a pathogenic role in human ulcerative colitis (UC) by producing autoantibodies that cause epithelial cell damage. Here we report on a patient with intractable UC who suffered from a severe exacerbation of UC after salvage therapy with rituximab, a B-cell-depleting anti-CD20-antibody. Methods: A 58-year-old patient with active long-standing UC and unresponsiveness or adverse events to mesalamine, corticosteroids, azathioprine, methotrexate, infliximab, leukapheresis, mycophenolate mofetil, and adalimumab received 375 mg/m2 rituximab. Results: A severe exacerbation of UC activity was noted upon therapy that required hospitalization. Subsequent studie…

medicine.medical_specialtyExacerbationSalvage therapyAzathioprineGastroenterologyInflammatory bowel diseaseAntibodies Monoclonal Murine-DerivedInternal medicinemedicineAdalimumabHumansImmunology and AllergySalvage TherapyB-Lymphocytesbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInterleukin-10ImmunologyColitis UlcerativeRituximabRituximabbusinessmedicine.drugInflammatory Bowel Diseases
researchProduct

Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis

1997

The mechanisms responsible for thyrocyte destruction in Hashimoto's thyroiditis (HT) are poorly understood. Thyrocytes from HT glands, but not from nonautoimmune thyroids, expressed Fas. Interleukin-1β (IL-1β), abundantly produced in HT glands, induced Fas expression in normal thyrocytes, and cross-linking of Fas resulted in massive thyrocyte apoptosis. The ligand for Fas (FasL) was shown to be constitutively expressed both in normal and HT thyrocytes and was able to kill Fas-sensitive targets. Exposure to IL-1β induced thyrocyte apoptosis, which was prevented by antibodies that block Fas, suggesting that IL-1β-induced Fas expression serves as a limiting factor for thyrocyte destruction. Th…

medicine.medical_specialtyFas Ligand Proteinmedicine.medical_treatmentThyroid GlandApoptosisPolymerase Chain ReactionThyroiditisFas ligandPathogenesisImmunoenzyme TechniquesInternal medicinemedicineTumor Cells CulturedHumansRNA Messengerfas ReceptorCells CulturedNucleic Acid Synthesis InhibitorsProtein Synthesis InhibitorsMultidisciplinaryMembrane GlycoproteinsChemistryThyroidThyroiditis AutoimmuneInterleukinAntibodies Monoclonalmedicine.diseaseFas receptorRecombinant ProteinsCytokinemedicine.anatomical_structureEndocrinologyApoptosisCytokinesInterleukin-1
researchProduct

Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

2020

medicine.medical_specialtyInterleukin-13Ocular surface diseasebusiness.industryMEDLINEEczemaDermatologyAtopic dermatitismedicine.diseaseAntibodies Monoclonal HumanizedDupilumabDermatologyDermatitis Atopicdupilumab atopic dermatitis ocular surface diseaseInfectious DiseasesmedicineHumansIn patientbusinessJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Islet beta-cell apoptosis triggered in vivo by interleukin-1beta is not related to the inducible nitric oxide synthase pathway: evidence for mitochon…

2003

IL-1beta is recognized as an effector cytokine contributing to islet beta-cell destruction during diabetes. We have previously shown in vitro that IL-1beta induces nitric oxide (NO) and beta-cell damage. Here, we show that IL-1beta administration in vivo to Wistar rats transiently increases manganese superoxide dismutase activity, whereas inducible NO synthase is not detected, and the levels of nitrate+nitrate do not change. Moreover, a significant decrease of mitochondrial aconitase, leading to a rise of hydroperoxides, and islet beta-cell apoptosis, involving caspase-3 and -8, is observed. Analysis of adhesion molecules in beta-cells showed that intercellular adhesion molecule-1 is highly…

medicine.medical_specialtyLipid PeroxidesNitric Oxide Synthase Type IIApoptosisBiologyMitochondrionIn Vitro TechniquesAconitaseNitric oxidechemistry.chemical_compoundIslets of LangerhansEndocrinologyIn vivoInternal medicinemedicineAnimalsRats WistarNitritesAconitate HydratasegeographyCaspase 8geography.geographical_feature_categoryNitratesCell adhesion moleculeCaspase 3Superoxide DismutaseIsletIntercellular Adhesion Molecule-1Caspase 9Cell biologyMitochondriaRatsNitric oxide synthaseEndocrinologyBiochemistrychemistryApoptosisCaspasesbiology.proteinNitric Oxide SynthaseInterleukin-1Endocrinology
researchProduct

Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and…

1997

We have tested whether tetracyclines (TETs) are able to protect mice from lipopolysaccharide (LPS)-induced shock, a cytokine-mediated inflammatory reaction. Mice, injected with a single dose of tetracycline base (TETb; 1.5, 10 and 20 mg/kg of body weight) or doxycycline (DOXY; 1.5 mg/kg), were significantly protected from a lethal intraperitoneal injection of LPS (500 micrograms per mouse). TETs acted in early events triggered in response to LSP; in fact, they were no longer significantly protective if injected more than 1 h after the injection of endotoxin. LPS-treated mice protected by TETs showed a significant inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin-1 alpha (IL…

medicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentIntraperitoneal injectionDown-RegulationAlpha (ethology)SpleenBiologyMicechemistry.chemical_compoundInternal medicinemedicineAnimalsPharmacology (medical)LungAntibacterial agentPharmacologyMice Inbred BALB CNitratesTumor Necrosis Factor-alphaTetracyclineShock SepticEndotoxemiaAnti-Bacterial AgentsNitric oxide synthaseInfectious DiseasesEndocrinologyCytokinemedicine.anatomical_structurechemistryDoxycyclineEnzyme InductionMacrophages Peritonealbiology.proteinCytokinesFemaleTumor necrosis factor alphaNitric Oxide SynthaseInjections IntraperitonealSpleenInterleukin-1Research ArticleAntimicrobial Agents and Chemotherapy
researchProduct

Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mi…

1998

Cytokines interact not only with membrane anchored receptors, but also with specific soluble receptors which circulate in the bloodstream. In general, soluble cytokine receptors such as soluble tumor necrosis factor receptor, soluble interleukin 1 receptor, and soluble interleukin 4 receptor compete with their membrane-bound counterparts for the ligands and therefore act as antagonists. In contrast, soluble receptors for cytokines of the interleukin-6 (IL-6) family complex with their ligands act agonistically. Interestingly, the complex of IL-6 and the soluble interleukin 6 receptor (sIL-6R) activates target cells that do not express the membrane-bound IL-6R and therefore cannot respond to …

medicine.medical_specialtyMice TransgenicInterleukin 1 receptor type IIInterleukin-1 receptorPathology and Forensic MedicineMiceNecrosisInterleukin-4 receptorInternal medicinemedicineAnimalsHumansReceptorInterleukin 6HyperplasiabiologyInterleukin-6Body WeightLiver NeoplasmsInterleukinAnimal ModelsOrgan SizeReceptors Interleukin-6EndocrinologyLiverHematopoiesis ExtramedullaryInterleukin-6 receptorCancer researchbiology.proteinInterleukin 1 receptor type ISpleenPlasmacytomaThe American Journal of Pathology
researchProduct

Responses to self and non-self intestinal microflora in health and inflammatory bowel disease.

1997

medicine.medical_specialtyT-LymphocytesImmunologyBiologyCross ReactionsInflammatory bowel diseaseGastroenterologyAntibodiesImmune tolerancePathogenesisMiceImmune systemCrohn DiseaseInternal medicinemedicineAnimalsHumansCrohn diseaseCross reactionsmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInterleukin-12Interleukin-10IntestinesInterleukin 10Disease Models AnimalImmunologyForecastingResearch in immunology
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab

2018

Hidradenitis suppurativa (HS) is a disorder of the apocrine gland causing a chronic, recurrent and painful inflammation. It is a disabilitating condition and, though many therapeutic options are available, the response is often ineffective in most cases and patients can present many recurrences with physical and psychological sequelae. Recent data had shown increased interleukin (IL)-17 serum levels in patients with HS. Psoriasis is a chronic immune-mediated inflammatory disorder and new evidences have shown the role of Th17 cells in its pathogenesis and the therapeutic efficacy of anti-IL-17 antibodies. We present a case of a patient suffering from psoriasis and HS successfully treated wit…

medicine.medical_specialtybusiness.industryInterleukin-17ApocrineInterleukinCase ReportInflammationDermatologymedicine.diseaseDermatologyPathogenesisHidradenitis suppurativa030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPsoriasismedicinePsoriasisHidradenitis suppurativaSecukinumabInterleukin 17medicine.symptombusinessAnnals of Dermatology
researchProduct